Cargando…
Discovery of Highly Potent p53-MDM2 Antagonists and Structural Basis for Anti-Acute Myeloid Leukemia Activities
[Image: see text] The inhibition of p53-MDM2 interaction is a promising new approach to non-genotoxic cancer treatment. A potential application for drugs blocking the p53-MDM2 interaction is acute myeloid leukemia (AML) due to the occurrence of wild type p53 (wt p53) in the majority of patients. Alt...
Autores principales: | Huang, Yijun, Wolf, Siglinde, Beck, Barbara, Köhler, Lisa-Maria, Khoury, Kareem, Popowicz, Grzegorz M., Goda, Sayed K, Subklewe, Marion, Twarda, Aleksandra, Holak, Tad A., Dömling, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical
Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985958/ https://www.ncbi.nlm.nih.gov/pubmed/24405416 http://dx.doi.org/10.1021/cb400728e |
Ejemplares similares
-
Artificial Macrocycles as Potent p53–MDM2 Inhibitors
por: Estrada-Ortiz, Natalia, et al.
Publicado: (2017) -
Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists
por: Koes, David, et al.
Publicado: (2012) -
Fragment-Based Library
Generation for the Discovery
of a Peptidomimetic p53-Mdm4 Inhibitor
por: Boltjes, André, et al.
Publicado: (2014) -
Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists
por: Neochoritis, Constantinos G, et al.
Publicado: (2019) -
Optimized Inhibitors of MDM2 via an Attempted Protein‐Templated Reductive Amination
por: van der Vlag, Ramon, et al.
Publicado: (2019)